Nonhuman primate antigenic cartography of SARS-CoV-2

Many thanks to everyone who's been involved in this great collaborative work.

Thus, NHP sera are suitable for the antigenic characterization of SARS-CoV-2 variants, which is particularly important in context of absence of human single exposure sera.

Importantly, we show that neutralization titers of NHPs and the derived antigenic map correspond well with human data.

Antigenic maps are integral part of strain selection process of COVID-19 vaccines. Here we show that BA.2.86, JN.1, KP.2, KP.3 and KZ.1.1.1 occupy a distant antigenic region, highlighting the antigenic evolution away from previous variants.

I'm very excited to share our recent paper describing the antigenic relationship of SARS-CoV-2 variants in Nonhuman primates for the first time. @BarouchLab @annetzl @lasradoN @JanineKimpel @Cambridge_Uni @MedUniInnsbruck https://t.co/srCzL1K5SG

Many thanks to everyone who's been involved in this great collaboration!

Thus we conclude that NHP sera are suitable for the antigenic characterization of SARS-CoV-2 variants, which is particularly important in the context of absence of human single exposure sera.

Moreover, we show that neutralization titers of NHPs and the derived antigenic map correspond well with human data.

We found that the recent variants BA.2.86, JN.1, KP.2, KP.3 and KZ.1.1.1 occupy a distant antigenic region.

Our new brief report on the neutralization of Omicron subvariant BA.2.87.1 is now out on @Els_Vaccine! A great and rapid team effort from @AnnikaRoessler @mrowe1625 @airisyc @BarouchLab https://t.co/TvyS6kXNyo

Special thanks to my friends and previous colleagues at Medizinische Universität Innsbruck (@JanineKimpel @LydiaRiepler @imed_tweets) for so many years we laughed and learned together !!

Excited to share that I recently joined the @BarouchLab @harvardmed/@BIDMChealth as a postdoctoral fellow. Leaving #Innsbruck wasn't easy for me, but I'm happy to continue my academic career in #Boston to dive deeper into the world of viral infections and vaccine development.

Our recent data on neutralization escape of BA.2.86, EG.5.1 and FL.1.5.1 is now out now! @BarouchLab @airisyc https://t.co/fuspcCP6Mg

Looking for a new PhD student @imed_tweets https://t.co/537S8QWSzf Please share

Having an awesome reunion with @lukpuc in innsbrooklyn. Thinking about the good times with @JordanDoesFlu, @gabagagan, @dishabhavsar and others at the @florian_krammer Lab in New York!

‘Cocktail’ vaccines could offer increased protection against future #COVID19 variants of concern @AnnikaRoessler @annetzl @JanineKimpel @Cambridge_Uni @imed_tweets https://t.co/lzHOgxxf6Y

Adapted vaccines combining two or more distinct variants should improve cross-neutralization and help combat future immune escape variants. Many thanks @annetzl and Derek Smith @Cambridge_Uni for this fantastic collaboration. @NatureComms @imed_tweets #KimpelLab

Innsbrucker Virologin @JanineKimpel für angepassten #Corona-#Impfstoff - Je mehr Kontakte mit verschiedenen Varianten durch #Impfung oder #Infektion, desto größer der Schutz https://t.co/T1ZYYJZ9hC @imed_tweets

BA.2 omicron is antigenically distinct from pre-omicron variants but also BA.1 omicron. Cross-neutralizing antibodies are generated after repeated exposures, even against variants not exposed to.